Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. In the past
ALL was intractable but now the survival probability is as high as 80–90%. Improved …

Improvements in risk-directed treatment and supportive care, together with increased
reliance on both national and international collaborative studies, have made childhood …

Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly
penetrant cancer predisposition condition. Recent reports of germline TP53 variants in …

Abstract Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05-001 tested a new
risk stratification system in children and adolescents with newly diagnosed acute …

Acute lymphoblastic leukaemia (ALL) is a prevalent form of pediatric cancer that accounts for
70–80% of all leukemias. Genome-based analysis, exome sequencing, transcriptomics and …

Primary refractory or relapsed pediatric leukemia yield significant morbidity and mortality,
with long-term survival rates< 40%. Here we present a post-hoc analysis assessing safety …

B-cell precursor acute lymphoblastic leukemia is the most common pediatric malignancy, but
its treatment needs to be modified to cause low acute toxicity and few late complications with …

In acute lymphoblastic leukemia (ALL), limited data are available on mTOR gene expression
in clinical samples and its role in predicting response to induction chemotherapy. mRNA …

Objectives Chromosome (G-banding) and fluorescence in situ hybridization (FISH) serve as
the primary methodologies utilized for detecting genetic aberrations in hematologic …

The cancer metabolic program alters bioenergetic processes to meet the higher demands of
tumor cells for biomass production, nucleotide synthesis, and NADPH-balancing redox …